Hepamet纤维化评分系统的开发与验证:一种识别非酒精性脂肪性肝病进展性纤维化患者的简易无创检测
研究基于意大利、法国、古巴和中国2452例NAFLD患者数据,开发并验证了基于血清标志物的Hepamet纤维化评分系统(HFS),用于识别进展性纤维化。
要点
- HFS由性别、年龄、HOMA评分、糖尿病、AST、白蛋白和血小板计数构成。
- HFS Cut-off 0.12和0.47识别进展性纤维化的特异性97.2%、敏感性74%。
核心结论
- HFS识别进展性纤维化的准确性优于FIB-4和NFS系统。
- Hepamet系统为决定是否进行肝活检提供了更大的净获益。
研究设计与样本
- 收集意大利、法国、古巴和中国2452例NAFLD患者数据。
- 使用西班牙训练队列(n=768)开发HFS,并在古巴(n=344)、意大利(n=288)、法国(n=830)和中国(n=232)队列中验证。
- HFS与NFS和FIB-4进行比较,评估AUROC、敏感性、特异性等指标。
主要发现
- 验证集中,HFS Cut-off 0.12和0.47识别进展性纤维化的特异性97.2%、敏感性74%、阴性预测值92%、阳性预测值76.3%、阳性似然比13.22、阴性似然比0.31。
- HFS不受患者年龄、BMI、转氨酶升高或糖尿病影响。
关键数值与推荐
- HFS变量包括患者性别、年龄、HOMA评分、糖尿病存在、AST水平、白蛋白水平和血小板计数。
- HFS Cut-off 0.12和0.47用于识别有无进展性纤维化。
临床怎么用
- HFS可用于识别NAFLD患者中进展性纤维化风险,指导肝活检决策。
- HFS在决策过程中提供更大净获益,减少不确定结果。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Fibrosis affects prognoses for patients with nonalcoholic fatty liver disease (NAFLD). Several non-invasive scoring systems have aimed to identify patients at risk for advanced fibrosis, but inconclusive results and variations in features of patients (diabetes, obesity and older age) reduce their diagnostic accuracy. We sought to develop a scoring system based on serum markers to identify patients with NAFLD at risk for advanced fibrosis. METHODS: We collected data from 2452 patients with NAFLD at medical centers in Italy, France, Cuba, and China. We developed the Hepamet fibrosis scoring system using demographic, anthropometric, and laboratory test data, collected at time of liver biopsy, from a training cohort of patients from Spain (n = 768) and validated the system using patients from Cuba (n = 344), Italy (n = 288), France (n = 830), and China (n = 232). Hepamet fibrosis score (HFS) were compared with those of previously developed fibrosis scoring systems (the NAFLD fibrosis score [NFS] and FIB-4). The diagnostic accuracy of the Hepamet fibrosis scoring system was assessed based on area under the receiver operating characteristic (AUROC) curve, sensitivity, specificity, diagnostic odds ratio, and positive and negative predictive values and likelihood ratios. RESULTS: Variables used to determine HFS were patient sex, age, homeostatic model assessment score, presence of diabetes, levels of aspartate aminotransferase, and albumin, and platelet counts; these were independently associated with advanced fibrosis. HFS discriminated between patients with and without advanced fibrosis with an AUROC curve value of 0.85 whereas NFS or FIB-4 did so with AUROC values of 0.80 (P = .0001). In the validation set, cut-off HFS of 0.12 and 0.47 identified patients with and without advanced fibrosis with 97.2% specificity, 74% sensitivity, a 92% negative predictive value, a 76.3% positive predictive value, a 13.22 positive likelihood ratio, and a 0.31 negative likelihood ratio. HFS were not affected by patient age, body mass index, hypertransaminasemia, or diabetes. The Hepamet fibrosis scoring system had the greatest net benefit in identifying patients who should undergo liver biopsy analysis and led to significant improvements in reclassification, reducing the number of patients with undetermined results to 20% from 30% for the FIB-4 and NFS systems (P < .05). CONCLUSIONS: Using clinical and laboratory data from patients with NAFLD, we developed and validated the Hepamet fibrosis scoring system, which identified patients with advanced fibrosis with greater accuracy than the FIB-4 and NFS systems. the Hepamet system provides a greater net benefit for the decision-making process to identify patients who should undergo liver biopsy analysis.
引用
- Ampuero J, Pais R, Aller R, et al. Development and Validation of Hepamet Fibrosis Scoring System-A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis. Clin Gastroenterol Hepatol. 2019. PMID: 31195161. doi:10.1016/j.cgh.2019.05.051
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。